Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novo-Nordisk A/S (OTC: NONOF).

Full DD Report for NONOF

You must become a subscriber to view this report.


Recent News from (OTC: NONOF)

Venture Capital Deals Of The Week: Tencent Led $3B Investment
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Group buying: Tencent ([[TCEHY]], [[TCTZF]]) Holdings reportedly led a $3B round in Pinduoduo, a Chinese...
Source: SeekingAlpha
Date: April, 14 2018 10:44
Fundsmith Annual Letter To Shareholders 2017
Read more ...
Source: SeekingAlpha
Date: January, 23 2018 07:36
Novo Nordisk: Still A Safe Bet Under One Condition
(Source: 2016 Annual Report) ( Approximately 1 in 11 people have diabetes in the USA. Nova Nordisk creates products that help these people control their diabetes.) Novo Nordisk A/S (NONOF) is a Danish healthcare company that develops, manufactures, and markets pharmaceuticals related ...
Source: SeekingAlpha
Date: January, 22 2018 10:02
DoctoRx Positions For 2018: Biotech Fights The Fed
Venerable SA contributor DoctoRx brings to the table a background as a physician and pharmaceutical inventor/entrepreneur to inform his value- and catalyst-driven investment analysis focused in biotech and healthcare. Seeking Alpha editor Rebecca M. Oliver caught up with DoctoRx to harves...
Source: SeekingAlpha
Date: December, 31 2017 09:00
Novo Needs New Blood Despite Q1 Relief
Novo Nordisk's (NVO) (NONOF) better-than-expected first quarter raised hopes that its new chief executive Lars Fruergaard Jørgensen has begun to turn things around, sending its shares up 7% yesterday. But there is still a long road ahead for Novo, which is more exposed than most to the ha...
Source: SeekingAlpha
Date: May, 04 2017 15:31
Snippets Roundup: Sanofi Diabetes Disappointment, And Amgen Pullback Signals CGRP Caution
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items. This week, April 24 to 28, 2017, we had thoughts on the following: Sanofi (SNY) diabetes disappointment a prelude to Novo (NONOF) report;Is Tesaro (TSRO) planning a Zejula combo for TSR-042?; Medicin...
Source: SeekingAlpha
Date: April, 28 2017 15:50
Lilly Assures Market As Diabetes Stumbles
As the diabetes wars have raged, Eli Lilly's (LLY) balanced portfolio has helped insulate it from the share price losses dealt to competitor Novo Nordisk (NONOF). But even Lilly can have an off quarter. Trulicity's growth was more than offset by below-consensus sales for Basaglar and Jardian...
Source: SeekingAlpha
Date: April, 26 2017 10:27
Corporate Venture Capital - Savior Of Medtech?
Big medtech and big pharma are taking a greater role in the funding of medical device start-ups. 2016 was the first year in which the corporate venture arms of the large strategics have put up more than 20% of the cash for early-stage medtech companies, EvaluateMedTech data show (see graph bel...
Source: SeekingAlpha
Date: March, 20 2017 12:08
Industry's Rare Disease Moves Pay Off
The pharmaceutical industry’s growing interest in orphan disease shows no sign of diminishing, and for good reason. The increased R&D investment in these indications in recent years has translated into a growing share of overall pharmaceutical sales, a new EvaluatePharma report find...
Source: SeekingAlpha
Date: February, 28 2017 12:11
Snippet Roundup: Deals For Boston And Astra; Data For Novo; An Approval For Biosurfit
Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items. Last week, November 28-December 2, 2016, we had thoughts on the following: Boston does an Mvalve on Neovasc; Bicycle rides to Astra deal; Novo’s costly devotion to Tresiba; Biosu...
Source: SeekingAlpha
Date: December, 06 2016 17:42

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1747.2047.2047.2047.201,111
2018-08-16N/A48.7027N/AN/A1,568
2018-08-15N/A48.7027N/AN/A909
2018-08-1448.0048.702748.702748.0048,122
2018-08-1346.89246.89246.89246.8923,755

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1410047,4330.2108Cover
2018-08-0932543375.0577Short
2018-08-084102,81014.5907Cover
2018-08-07290290100.0000Short
2018-08-06400400100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NONOF.


About Novo-Nordisk A/S (OTC: NONOF)

Logo for Novo-Nordisk A/S (OTC: NONOF)

Novo Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products OAD . Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management NovoSeven , growth hormone therapy, hormone replacement therapy and other products.

 

Contact Information

 

 

Current Management

  • Lars A. Sorensen / President, CEO
  • Kaare Schultz / COO
  • Jesper Brandgaard / CFO

Current Share Structure

     


    Recent Filings from (OTC: NONOF)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 09 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 08 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 02 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 01 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 01 2018

     

     


    Daily Technical Chart for (OTC: NONOF)

    Daily Technical Chart for (OTC: NONOF)


    Stay tuned for daily updates and more on (OTC: NONOF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: NONOF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NONOF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NONOF and does not buy, sell, or trade any shares of NONOF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/